The Israeli Ministry of Health has Approved Kanabo Research's Medical Cannabis Vaporizer as a Medical Device

Rehovot, Israel (ots/PRNewswire) -

Israel becomes the first country in the world to grant medical
device approval for a medical cannabis vaporizer

Kanabo Research, a Tel-Aviv-based medical cannabis R&D company, is
pleased to announce that the Israeli Ministry of Health has granted
initial approval as a medical device to its VapePod vaporizer
product. This action makes Israel the first county in the world to
grant medical device approval to a vaporizer for the use of medical
cannabis extracts and formulations.

In addition, Kanabo has initiated initial pre-clinical trials of
the company's targeted formulations for sleep disorders, designed for
use with the approved VapePod medical cannabis vaporizer, and is
achieving impressive results in early findings.

The combination of the approved vaporizer and the targeted
formulations will enable medical cannabis patients to receive more
effective, consistent, and accurate dosing and delivery methods than
currently accepted medical cannabis treatment methods. Kanabo has two
patents in the process of registration regarding the targeted
formulations of medical cannabis extracts for sleep disorders, as
well as the initial approval of the VapePod vaporizer by the Medical
Cannabis Unit of the Israeli Ministry of Health.

Most medical cannabis patients today consume their cannabis by
smoking - despite all of the known risks. The VapePod medical
vaporizer enables patients to inhale their medical cannabis without
the risks of smoking. Studies have shown that inhaling cannabis is
significantly more effective than other delivery methods, and the
VapePod vaporizer allows patients to still utilize the benefits of
inhalation. The next version of the device - VapePod MD - will also
monitor patient usage and gather usage data for caregivers, doctors,
and research applications.

"This approval is a significant announcement for the medical
cannabis patients in Israel who will be able to use the medical
vaporizer for the first time," said Avihu Tamir, co-founder and CEO
of Kanabo Research. "We expect that due to the transition of most of
the cannabis consumers to the use of vaporizers, our company is
projected to reach 10 million dollars in sales within three years in
the Israeli market, while the Israeli cannabis market is expected to
reach 100 million dollars in sales within three years. The Israeli
market is a platform to deliver our technology to global markets in
North America and Europe."

ots Originaltext: Kanabo Research
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Gil Kraiem
+972-50-5703090

Original-Content von: Kanabo Research, übermittelt durch news aktuell